Viral resistance patterns selected by antiretroviral drugs and their potential to guide treatment choice

Bibliography

• WET X, GHOSH SK, TAYLOR ME et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (1995) 373:117–122.
   Google Scholar
• HO DD, NEUMANN AU, PERELSON AS et al.: Rapid turnover of plasma virions and CD 4 lymphocytes in HIV-1 infection. Nature (1995) 373:123-126. Viral dynamics studies.
   Google Scholar
• MANSKY LM, TEMIN HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than predicted from fidelity of purified reverse transcriptase. J. Virol (1995) 69:5087–5094.
   PubMed Web of Science ®Google Scholar
• SCHINAZI RF, LLOYD RM, RAMANATHAN CS, TAYLOR EW: Antiviral drug resistance mutations in human immu-nodeficiency virus type 1 reverse transcriptase occur in specific RNA structural regions. Antimicrob. Agents Chemother. (1994) 38:268–274.
   PubMed Web of Science ®Google Scholar
• COFFIN JM: HIV population dynamics in vivo: implica-
   Google Scholar
• ?tions for genetic variation, pathogenesis and therapy. Science (1995) 267:483-489. Perspectives on resistance and disease pathogenesis.
   Google Scholar
• HASELTINE WA, WONG-STAAL F: The molecular biologyof the AIDS virus. SM. Am. (1989) 259:34–42.
   Google Scholar
• SAAG MS, HAHN BA, GIBBONS J etal.: Extensive variationof human immunodeficiency virus type lin vivo. Nature (1988) 334:440–444.
   Google Scholar
• KUNZI MS, GROOPMAN JE: Identification of a novel human immunodeficiency virus strain cytopathic to megakaryocytic cells. Blood (1993) 81:3336–3342.
   PubMed Web of Science ®Google Scholar
• CONNOR RI, HO DD: Human immunodeficiency virus type 1 variants with increased replicative capacity de-velop during the asymptomatic stage before disease progression. J. Vim]. (1994) 68:4400–4408.
   Web of Science ®Google Scholar
• LEIGH-BROWN AJ, RICHMAN DD: HIV-1: gambling on the evolution of drug resistance? Nature Med. (1997) 3:268-271. The role of chance.
   Google Scholar
• MOHRI H, SINGH MK, CHING WTW, HO DD: Quantitation of zidovudine -resistant human immunodeficiency vi-rus type 1 in the blood of treated and untreated patients. Proc. Natl. Acad. Sci. USA (1993) 90:25–29.
   PubMed Web of Science ®Google Scholar
• NAJERA I, RICHMAN DD, OLIVARES I et at Natural occur-rence of drug resistance mutations in the reverse tran-scriptase of human immunodeficiency virus type 1 isolates. AIDS Res. Hum. Retroldr. (1994) 10:1479–1488.
   PubMed Web of Science ®Google Scholar
• NAJERA I, HOLGUIN A, QUIRONES-MATEU E et al.: Poi gene quasi-species of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. (1995) 69:23–31.
   PubMed Web of Science ®Google Scholar
• FROST SDW, MCLEAN AR: Quasi-species dynamics and the emergence of drug resistance during zidovudine therapy of HIV infection. AIDS (1994) 8:323–332.
   PubMed Web of Science ®Google Scholar
• KELLAM P, BOUCHER CAB, TIJNAGAL JMGH, LARDER BA: Zidovudine treatment results in the selection of human immunodeficiency virus type 1 variants whose geno- types confer increasing levels of drug resistance. J. Gen. Vim]. (1994) 75:341–351.
   PubMed Web of Science ®Google Scholar
• DE JONG MD, SCHUURMAN R, LANGE JMA, BOUCHERCAB: Replication of a pre-existing resistant HIV-1 sub-population in vivo after introduction of a strong selec-tive pressure. Antiviral Ther. (1996) 1:33–41.
   PubMedGoogle Scholar
• PRASAD VR, DROSOPOULOS WC, HAMBURGH ME: Ap-proaches to control of drug resistance in HIV: the role of increased polymerase fidelity. AIDS Res. Hum. Retrovir. (1996) 12:959–963.
   PubMed Web of Science ®Google Scholar
• CLELAND A, WATSON HG, ROBERTSON P, LUDLAM CA,LEIGH BROWN AJ: Evolution of zidovudine resistance-associated genotypes in human immunodeficiency vi-rus type 1-infected patients. AIDS Res. Hum. Retroldr. (1996) 12:6–18.
   Google Scholar
• CHOW YK, HIRSCH MS, MERRILL DP et al.: Use of evolu-tionary limitations of 11IV-1 multidrug resistance to optimize therapy. Nature (1993) 361:650–653.
   PubMed Web of Science ®Google Scholar
• COFFIN JM: Genetic diversity and evaluation of retroviruses. Curr. Top. MicrobioL ImmunoL (1992) 176:143–164.
   PubMed Web of Science ®Google Scholar
• BOUCHER CAB, O'SULLIVAN E, MULDER JW et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-posi-tive subjects. J. Infect. Dis. (1992) 165:105–110.
   Google Scholar
• MOLLA A, KORNEYEVA M, GAO Q et al.: Ordered accu-mulation of mutations in HIV protease confers resis-tance to ritonavir. Nature Med. (1996) 2:760–766.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM et al: In vivo emergence of 11IV-1 variants resistant to multiple pro-tease inhibitors. Nature (1995) 374:569–571.
   PubMed Web of Science ®Google Scholar
• ROOKE R, TREMBLAY M, SOUDEYNS H et al.: Isolation of drug-resistant variants of 11IV-1 from patients on long-term zidovudine therapy. AIDS (1989) 3:411–415.
   PubMed Web of Science ®Google Scholar
• ALBERT J, WAHLBERG J, LUNDEBERG J et al.: Persistence of azidothymidine-resistant human immunodeficiency virus type 1 RNA genotypes in post-treatment sera. J. Virol. (1992) 66:5627–5630.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLEIF WA, BLAHY OM et al: Evidence for the existence of long-lived genetic reservoirs of 11IV-1 in infected patients. Fourth International HIV Drug-Resis-tance Workshop. Sardinia (1995). Abstract 82.
   Google Scholar
• BHIVA GUIDELINES CO-ORDINATING COMMITTEE: British HIV association guidelines for antiretroviral treat-ment of HIV seropositive individuals. Lancet (1997) 349:1086-1092. Current treatment guidelines for the UK.
   Google Scholar
• STUYVER L, WYSEUR A, ROMBOUT A et al.: Line probe assay for rapid detection of drug-selected mutations in the Human immunodeficiency virus Type 1 reverse transcriptase gene. Antimicrob. Agents Chemother. (1997) 41:284–291.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Current knowledge of HIV-1 reverse tran-scriptase (RI') mutations selected during nucleoside analogue therapy. The potential to use resistance data to guide clinical decisions. J. Antimicrob. Chemother. (1997). (In Press.) Using the LIPA test in clinical practice.
   Google Scholar
• GAO WY, AGBARIA R, DRISCOLL JS, MITSUYA H: Diver- gent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2'3'-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. (1994) 269:12633–12638.
   PubMed Web of Science ®Google Scholar
• BALZARINI J, PAUWELS R, BABA M et al.: The in vitro and in vivo antiretrovirus activity and intracellular metabo-lism of 3'-azido-2', 3'-dideoxythymidine and 2', 3'-dide-oxycytidine are highly dependent on cell species. Biochem. Pharmacol (1988) 37:897–903.
   PubMed Web of Science ®Google Scholar
• BARRY M, WILD M, VEAL G et al.: Zidovudine phospho-rylation in HIV-infected patients and seronegative vol-unteers. AIDS (1994) 8:F1–F5.
   PubMed Web of Science ®Google Scholar
• STRETCHER BN, PESCE J, FRAME PT, GREENBERG KA, STEIN DS: Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity. AIDS (1994) 8:763–769.
   PubMed Web of Science ®Google Scholar
• DIANZANI F, ANTONELLI G, TURRIZIANI 0 et al.: Zi-dovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Res. Hum. Retroldr. (1994) 10:1471–1478.
   Google Scholar
• BACK DJ, HAGGARD PG, VEAL GJ, BARRY MG: Intracellu-lar phosphorylation interactions between nucleoside analogues. Fifth European Conference on Clinical Aspects and Treatment of IRV Infection. Copenhagen (1995). Abstract 41.
   Google Scholar
• BRANDI G, PUDDU P, CASABIANCA A, CIANFRIGLIA M,MAGNANI M: The inhibitory effect of ddC on human immunodeficiency virus replication diminishes in cells that are chronically exposed to the drug. Antiviral Chem. Chemother. (1997) 8:113–119.
   Web of Science ®Google Scholar
• CHENG N, MERRIL BM, PAINTER GR, FRICK LW, FURMAN PA: Identification of the nucleotide binding site of HIV-1 reverse transcriptase using dTTP as a photoaffinity label. Biochemistry (1993) 32:7630–7638.
   PubMed Web of Science ®Google Scholar
• ERICKSON JW, BURT SK: Structural mechanisms of HIV drug resistance. Ann. Rev. Pharmacol. Toxicol (1996) 36:545-571. Review of molecular aspects of resistance.
   Google Scholar
• TANTILLO C, DING J, JACOBO-MOLINA A et al.: Locations of the anti-AIDS drug binding sites and resistance mu-tations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J. Mol. Biol. (1994) 243:369–387.
   Google Scholar
• SARAFIANOS SG, PANDEY VN, KAUSHIK N, MODAK MJ:Glutamine 151 participates in the substrate dNTP bind-ing function of HIV-1 reverse transcriptase. Biochemistry (1995) 34:7207–7216.
   PubMed Web of Science ®Google Scholar
• LARDER BA, DARBY G, RICHMAN DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during pro-longed therapy. Science (1989) 243:1731–1734.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, GRIMES JM, LAGAKOS SW: Effect of stage of disease and drug dose on zidovudine susceptibilities of isolates of human immunodeficiency virus. J. AIDS (1990) 3:743–746.
   PubMed Web of Science ®Google Scholar
• JAPOUR AJ, WELLES S, D'AQUILA RT et al.: Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from pa-tients after long-term zidovudine treatment./ Infect. Dis. (1995) 171:1172–1179.
   Google Scholar
• SMITH MS, KOERBER KL, PAGANO JS: Long-term persist-ence of zidovudine resistance mutations in plasma isolates of human immunodeficiency virus type 1 of © Ashley Publications Ltd. All rights reserved. Exp. Opin. Invest. Drugs (1997) 6(8) dideoxyinosine-treated patients removed from zi- dovudine therapy. J. Infect. Dis. (1994) 169:184–188.
   Google Scholar
• CALIENDO AM, SAVARA A, AN D et al.: Effects of zi-dovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and replicative capacity. J. Vim]. (1996) 70:2146–2153.
   Web of Science ®Google Scholar
• ERICE A, MAYERS DL, STRIKE DG et al: Primary infection with zidovudine-resistant human immunodeficiency virus type 1. New EngL J. Med. (1993) 328:1163–1165.
   PubMed Web of Science ®Google Scholar
• ANGARANO G, MONNO L, APPICE A et al: Transmission of zidovudine-resistant 11IV-1 through heterosexual contacts. AIDS (1994) 8.
   Google Scholar
• PERRIN L, YERLY S, RAKIK A et al.: Transmission of 215 mutants in primary HIV infection and analysis after 6 months of ZDV. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 21.
   Google Scholar
• HARZIC M, PATEY 0, FERCHAL F et al.: AZT resistance mutations in virus from patients with recent HIV infec-tion. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 26.
   Google Scholar
• GARCIA-LERMA G, SORIANO V, GOMEZ-CANO M et al.: Prevalence of zidovudine-resistant 11IV-1 among rapid progressors. AIDS (1996) 10:1292–1293.
   PubMed Web of Science ®Google Scholar
• BOUCHER CAB, TERMETTE M, LANGE JMA et al.: Zi-dovudine sensitivity of human immunodeficiency vi-ruses from high-risk, symptom-free individuals during therapy. Lancet (1990) 336:585–590.
   PubMed Web of Science ®Google Scholar
• LOPEZ-GALINDEZ C, ROJAS JM, NAJERA R, RICHMAN DD, PERUCHO M: Characterization of genetic variation and AZT resistance mutations of HIV by the RNAse mis-match cleavage method. Proc. Natl. Acad. Sci. USA (1991) 88:4280–4284.
   PubMed Web of Science ®Google Scholar
• LARDER BA, KELLAM P, KEMP SD: Zidovudine resistance predicted by direct detection of mutants in DNA from HIV-infected lymphocytes. AIDS (1991) 5:137–144.
   PubMed Web of Science ®Google Scholar
• DE JONG MD, VEENSTRA J, STILIANAKIS N et al.: Return to baseline values of 11IV-1 RNA load during zidovudine treatment is associated with the emergence of K7OR mutant virus. Fourth International HIV drug-resistance Workshop. Sardinia (1995). Abstract 20.
   Google Scholar
• MAYERS DL, MCCUTCHAN FE, SANDERS-BUELL EE et al.: Characterization of HIV isolates arising after prolonged zidovudine therapy. J. AIDS (1992) 5:749–759.
   PubMed Web of Science ®Google Scholar
• ST CLAIR MK MARTIN JL, TUDOR-WILLIAMS G et al.: Resistance to ddI and sensitivity to AZT induced by a mutation in 11IV-1 reverse transcriptase. Science (1991) 253:1557–1559.
   Google Scholar
• ERON JJ, CHOW YK, CALIENDO AM et al: Po/mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivo. Antimi-crob. Agents Chemother. (1993) 37:1480–1487.
   PubMed Web of Science ®Google Scholar
• TACHEDJIAN G, MELLORS J, BAZMI H, BIRCH C, MILLS J: Zidovudine resistance is suppressed by mutations con-ferring resistance of human immunodeficiency virus type 1 to foscarnet. J. Virol (1996) 70:7171–7181.
   PubMed Web of Science ®Google Scholar
• LARDER BA: 3'Azido-3' deoxythymidine resistance sup-pressed by a mutation conferring human immunodefi-ciency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1992) 36:2664–2669.
   PubMed Web of Science ®Google Scholar
• BOUCHER CAB, CAMMACK N, SCHIPPER P et al.: High-level resistance to (-)enantiomeric 2'-deoxy-3'-thiacytidine (3TC) in vitro is due to one amino acid substitution in the catalytic site of 11IV-1 reverse tran-scriptase. Antimicrob. Agents Chemother. (1993) 37:2231–2234.
   PubMed Web of Science ®Google Scholar
• TISDALE M, KEMP SD, PARRY NR, LARDER BA: Rapid invitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a muta-tion in the YMDD region of reverse transcriptase. Proc. Nati Acad. ScL USA (1993) 90:5633–5656.
   PubMedGoogle Scholar
• LARDER BA, KEMP SD, HARRIGAN PR: Potential mecha-nism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science (1995) 269:696–699.
   PubMed Web of Science ®Google Scholar
• ZHANG D, CALIENDO AM, ERON JJ et al.: Resistance to2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. (1994) 38:282–287.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, GUATELLI JC, GRIMES J, TSIATIS A, GIN-GERAS TR: Detection of mutations associated with zi-dovudine resistance in human immunodeficiency virus by use of the polymerase chain reaction. J. Infect. Dis. (1991) 164:1075–1081.
   PubMed Web of Science ®Google Scholar
• LACEY SF, LARDER BA: Mutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 re-verse transcriptase, which are significant in nucleoside analog resistance. J. Vim]. (1994) 68:3421–3424.
   Web of Science ®Google Scholar
• LARDER BA, CHFSEBRO B, RICHMAN DD: Susceptibilities of zidovudine-susceptible and resistant human immu-nodeficiency virus isolates to antiviral agents deter-mined by using a quantitative plaque reduction assay. Antimicrob. Agents Chemother. (1990) 34:436–441.
   PubMed Web of Science ®Google Scholar
• ROOKE R, PARNIAK MA, TREMBLAY M et al.: Biological comparisons of wild-type and zidovudine-resistant iso-lates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugs. Antimicrob. Agents Chemother. (1991) 35:988–991.
   PubMed Web of Science ®Google Scholar
• DIMITROV DH, HOLLINGER FB, BAKER CJ etal.: Study of human immunodeficiency virus resistance to 2'3'-dide-oxyinosine and zidovudine in sequential isolates from pediatric patients on long-term therapy. J. Infect. Dis. (1993) 167:818–823.
   Google Scholar
• JAPOUR AJ, CHATIS PA, EIGENRAUCH HA, CRUMPACKERCS: Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA-RNA hybridization. Proc. Natl. Acad. Sci. USA (1991) 88:3092–3096.
   PubMed Web of Science ®Google Scholar
• MAYERS DL, JAPOUR AJ, ARDUINO J-M et al.: Dideoxynu-cleoside resistance emerges with prolonged zidovudine therapy. Antimicrob. Agents Chemother. (1994) 38:307–314.
   PubMed Web of Science ®Google Scholar
• QUINONES-MATEU ME, ALBRIGHT JL, MARIOS J-P et al.: A unique mechanism for zidovudine resistance and evi-dence of zidovudine-mediated cross-resistance to other nucleoside analogues by zidovudine-resistant viruses. International Workshop on HIV Drug Resistance, Treatment Strategiesand Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 10. New data on ZDV cross-resistance.
   Google Scholar
• HOLODNIY M, KATZENSTEIN D, MOLE L, WINTERS M, MERRIGAN T: Human immunodeficiency virus reverse transcriptase Codon 215 mutations diminish virologic response to didanosine-zidovudine therapy in subjects with non-syncytium-inducing viral phenotype. J. Infect. Dis. (1996) 174:854–857.
   PubMed Web of Science ®Google Scholar
• SYLVESTER S, CALIENDO A, AN D et al: 11IV-1 resistance mutations and plasma RNA during WV and ddC com-bination therapy. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 47.
   Google Scholar
• DAVEY RT, CHAITT DG, REED GF et al.: Randomized, controlled Phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected pa-tients. Antimicrob. Agents Chemother. (1996) 40:1657–1664.
   PubMed Web of Science ®Google Scholar
• DEMETER LM, NAWAZ T, MORSE G et al: Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J. Infect. Dis. (1995) 172:1480–1485.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, WINTERS MA, JELLINGER RM, MERRIGAN TC:Zidovudine resistance reverse transcriptase mutations during didanosine monotherapy. J. Infect. Dis. (1996) 174:448–449.
   PubMed Web of Science ®Google Scholar
• UN P-F, SAMANTA H, ROSE RE et al: Genotypic and phenotypic analysis of human immunodeficiency virus type 1 isolates from patients on prolonged stavudine therapy. J. Infect. Dis. (1994) 170:1157–1164.
   PubMed Web of Science ®Google Scholar
• SHIRASAKA T, YARCHOAN R, O'BREIN MC et al: Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxy-cytidine, and dideoxyinosine: an in vitro comparative study. Proc. Nail. Acad. Sci. USA (1993) 90:562–566.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. An-timicrob. Agents Chemother. (1993) 37:1207–1203.
   PubMed Web of Science ®Google Scholar
• SHIRASAKA T, YARCHOAN R, O'BRIEN MC et al: Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxy-cytidine and dideoxyinosine: an in vitro comparative study. Proc. Natl. Acad. Sci. USA (1993) 90:562–566.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, MENG TC, SPECTOR SA et al.: Resistance to AZT and ddC during long-term combination therapy in patients with advanced infection with human immu-nodeficiency virus. J. AIDS (1994) 7:135–138.
   PubMed Web of Science ®Google Scholar
• CRAIG JC, MOYLE GJ: The development of resistance of
   Google Scholar
• •HIV-1 to ddC. AIDS (1997) 11:271-280. Definitive review of ddC resistance.
   Google Scholar
• KOZAL MJ, KROODSMA K, WINTERS MA et al: Didanosine resistance in HIV-infected patients switched from zi-dovudine to didanosine monotherapy. Ann. Intern. Med. (1994) 121:263–268.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, IVERSEN AKN, WINTERS MA et al.: Drug resistance and heterogeneous long-term virologic re-sponses of human immunodeficiency virus type 1-infected subjects to zidovudine and didanosine combi-nation therapy. J. Infect. Dis. (1995) 172:70–78.
   PubMed Web of Science ®Google Scholar
• BOYER PL, TANTILLO C, JACOBO-MOLINA A et al.: Sensi-tivity of wild-type human immunodeficiency virus type 1 reverse transcriptase to dideoxynucleotides depends on template length; the sensitivity of drug-resistant mutants does not. Proc. Natl. Acad. Sci. USA (1994) 91:4882–4886.
   PubMed Web of Science ®Google Scholar
• GU Z, GAO Q, FANG H et aL: Identification of a mutationat codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resis-tance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. (1994) 38:275–281.
   PubMed Web of Science ®Google Scholar
• SHARMA PL, CHATIS PA, DOGON A et al.: AZT-relatedmutation Lys70Arg in reverse transcriptase of human immunodeficiency virus type 1 confers decrease in susceptibility to ddATP in in vitro inhibition assay. Virology (1996) 223:365–369.
   PubMed Web of Science ®Google Scholar
• FITZGIBBON JE, HOWELL RM, HABERZETTL CA et al.: Human immunodeficiency virus type 1 pol gene muta-tions which cause decreased susceptibility to 2',3'-dide-oxycytidine. Antimicrob. Agents Chemother. (1992) 36:153–157.
   PubMed Web of Science ®Google Scholar
• FITZGIBBON JE, FARNHAM AE, SPERBER SJ, KIM H, DUBIN DT: Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J. ViroL (1993) 67:7271–7275.
   PubMed Web of Science ®Google Scholar
• ERON JJ, JOHNSON VA, MERRILL DP et al.: Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vi-tro. Antimicrob. Agents Chemother. (1992) 36:1559–1562.
   PubMed Web of Science ®Google Scholar
• JOHNSON VA, MERRILL DP, VIDELER JA et al.: Two-drug combinations of zidovudine, didanosine, and recombi-nant interferon alpha inhibit replication of zidovudine-resistant human immunodeficiency virus type 1 synergistically in vitro. J. Infect. Dis. (1991) 164:646–655.
   PubMed Web of Science ®Google Scholar
• MENG RC, FISCHL MA, BOOTA AM et al.: Combinationtherapy with zidovudine and dideoxycytidine in pa-tients with advanced human immunodeficiency virus infection: a Phase I/II study. Ann. Intern. Med. (1992) 116:13–20.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, COOMBES RW, FISCHL MA et al: Combina-tion therapy with zidovudine and didanosine com-pared with zidovudine alone in HIV-1 infection. Ann. Intern. Med. (1993) 119:786–793.
   PubMed Web of Science ®Google Scholar
• SCHOOLEY RT, RAMIREZ-RONDA C, LANGE JMA et al.:Virologic and immunologic benefits of initial combina-tion therapy with zidovudine and zalcitabine or di-danosine compared with zidovudine alone. J. Infect. Dis. (1996) 173:1354–1366.
   PubMed Web of Science ®Google Scholar
• LOVEDAY C, DELTA VIROLOGY GROUP: 11IV-1 genotypicand phenotypic resistance in Delta patients. Third Con-ference on Retroldruses and Opportunistic Infections. Wash-ington DC (January-February 1996). Abstract 107.
   Google Scholar
• LARDER BA, KELLAM P, KEMP SD: Convergent combina-tion therapy can select viable multidrug resistant HIV-1 in vitro. Nature (1993) 365:451–453.
   PubMed Web of Science ®Google Scholar
• SHAFER RW, KOZAL MJ, WINTERS MA et al.: Combinationtherapy with zidovudine and didanosine selects for drug resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. J. Infect. Dis. (1994) 169:722–729.
   PubMed Web of Science ®Google Scholar
• SHIRASAKA T, KAVLICK MF, VENO T et al.: Emergence ofhuman immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc. Nati Acad. Sci. USA (1995) 92:2398–2402.
   PubMed Web of Science ®Google Scholar
• © Ashley Publications Ltd. All rights reserved. Exp. Opin. Invest. Drugs (1997) 6(8)
   Google Scholar
• SHAFER RW, WINTERS MA, IVERSEN AKN, MERIGAN TC:Genotypic and phenotypic changes during culture of a multinucleoside-resistant human immunodeficiency virus type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob. Agents Chemother. (1996) 40:2887–2890.
   PubMed Web of Science ®Google Scholar
• SCHMIT J-C, COGNIAUX J, HERMANS P et al: Multiple drug resistance to nucleoside analogues and nonnucleoside reverse transcriptase inhibitors in an efficiently repli-cating human immunodeficiency virus type 1 patient strain. j Infect. Dis. (1996) 174:962–968.
   PubMed Web of Science ®Google Scholar
• SCHUURMAN R, NIJHUIS M, VAN LEEUVVEN R et al: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus popula-tions in persons treated with lamivudine (3TC). I. Infect. Dis. (1995) 171:1411–1419.
   PubMed Web of Science ®Google Scholar
• KAVLIK MF, SHIRASAKA T, KOJIMA E etal.: Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (-)-2', 3'-dideoxy-3'-thiacytidine. An-tiviral Res. (1995) 28: 133–146.
   Google Scholar
• WAINBERG MA, DROSOPOULOS WC, SALOMON H et al: Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase. Science (1996) 271:1282–1284.
   PubMed Web of Science ®Google Scholar
• GAO Q, GU ZX, PARNIAK MA et al: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dide-oxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob. Agents Chemother. (1993) 37:1390–1392.
   PubMed Web of Science ®Google Scholar
• SCHINAZI RF, LLOYD RJ, NGUYEN M-H et al: Charac-terization of human immunodeficiency viruses resis-tant to oxathiolane-cytosine nucleosides. Antimicrob. Agents Chemother. (1993) 37:875–881.
   PubMed Web of Science ®Google Scholar
• WAINBERG MA, SALOMON H, GU Z et al.: Development of 11IV-1 resistance to (-)2'-deoxy-3'-thiacytidine in pa-tients with AIDS or advanced AIDS-related complex. AIDS (1995) 9:351–357.
   PubMed Web of Science ®Google Scholar
• NIJHUIS M, DE JONG D, VAN LEEUVVEN R et al.: The rise in 11IV-1 RNA viral load during 3TC/AZT combination therapy is associated with the selection of viruses resistant to both 3TC and AZT. Fourth International Workshop on IRV Drug Resistance. Sardinia (1995). Abstract 52.
   Google Scholar
• KURITZKES DR, QUINN JB, BENOIT SL et aL: Drug resis-tance and virologic response to NUCA3001, a random-ized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus3TC in previously untreated patients. AIDS (1996) 10:975–981.
   PubMed Web of Science ®Google Scholar
• HARRIGAN PR, BLOOR S, KINGHORN I, THE LAMIVUDINE EUROPEAN HIV WORKING GROUP, LARDER BA:Virologi-cal response to AZT/3TC combination therapy in AZT experienced patients (Trial NUCB3002). Fourth Interna-tional Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 54.
   Google Scholar
• BARTLETT JA, BENOIT S, SEPULVEDA G et al. THE NORTH AMERICAN HIV WORKING PARTY, RUBIN M: The safety and efficacy of lamivudine plus zidovudine combina-tion therapy compared to zalcitabine plus zidovudine in the treatment of zidovudine-experienced HIV-in-fected patients with CD4 cell counts 100-300mm3: a randomized, double-blind multicenter, controlled trial. Ann. Intern. Med. (1996) 125:161–172.
   PubMed Web of Science ®Google Scholar
• ERON JJ, BENOIT SL, JEMSEK J et al.: Treatment with lamivudine, zidovudine, or both in 'IN-positive pa-tients with 200 to 500 CD4 + cells per cubic millimeter. New EngL J. Med. (1995) 333:1662–1669.
   PubMed Web of Science ®Google Scholar
• KATLAMA C, INGRAND D, LOVEDAY C et al. THE LAMI-VUDINE EUROPEAN HIV WORKING GROUP: Safety and efficacy of lamivudine (3TC)/zidovudine (ZDV) in an-tiretroviral naive 11IV-1 infected patients: a comparison with zidovudine monotherapy. JAMA (1996) 276:118–125.
   PubMed Web of Science ®Google Scholar
• STASZEWSKI S, LOVEDAY C, PICAZO JJ et al. THE LAMI-VUDINE EUROPEAN HIV WORKING GROUP: Safety and efficacy of lamivudine/zidovudine combination in zi-dovudine experienced HIV-i infected patients: a com-parison with zidovudine monotherapy. JAMA (1996) 276:111–117.
   PubMed Web of Science ®Google Scholar
• GOULDEN MG, CAMMACK N, HOPEWELL PL, PENN CR, CAMERON JM: Selection in vitro of an 11IV-1 variant resistant to both lamivudine (3TC) and zidovudine. AIDS (1996) 10:101–115.
   PubMed Web of Science ®Google Scholar
• KEMP SD, KOHLI A, LARDER BA: Genotypic charac-terisation of an 11IV-1 mutant co-resistant to AZT and 3TC. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 51.
   Google Scholar
• JOHNSON VA, WAGNER SF, OVERBAY CB et al.: Drug resistance and viral load in NUCA 3002: a comparative trial of lamivudine (3TC) (high or low dose)/zidovudine (ZDV) combination therapy vs. ZDV/ dideoxycytidine (ddC) combination therapy in ZDV-experienced 24 weeks) patients (CD4 cells 100-300/mm3). Fourth Inter-national Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 55.
   Google Scholar
• KEMP SA, BLOOR S FOR THE FASP RESISTANCE STUDY GROUP: Two distinct mutational pathways in 11IV-1 RT confer zidovudine/lamivudine dual resistance. Interna-tional Workshop on HIV Drug Resistance, Treatment Strate-gies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 11.
   Google Scholar
• CAESAR CO-ORDINATING COMMITTEE: Randomised trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with 11IV-1 infection: the CAESAR trial. Lancet (1997) 349:1413–1421.
   PubMed Web of Science ®Google Scholar
• GULICK RM, MELLORS J, HAVLIR D et al.: Potent and sustained antiretroviral activity of indinavir (DV), zi-dovudine (ZDV) and Lamivudine. XI International Con-ference on AIDS. Vancouver (July 1996). Abstract Th.B.931.
   Google Scholar
• GU Z, GAO Q, LI X, PARNIAK MA, WAINBERG MA: Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene encodes cross resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. j ViroL (1992) 66:7128–7135.
   PubMed Web of Science ®Google Scholar
• LACEY SF, LARDER BA: Novel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3' didehydro-2',3-dide-oxythymidine in cell culture. Antimicrob. Agents Chemother. (1994) 38:1428–1432.
   PubMed Web of Science ®Google Scholar
• GU Z, GAO Q, FANG H et al.: Identification of novel mutations that confer drug resistance in the human immunodeficiency virus polymerase gene. Leukemia (1994) 8\(Suppl. 1):5166–5169.
   Google Scholar
• SHEPP D, ASHRAF A, MILLAN C, PERGOLIZZI R: Pheno-typic and genotypic characterisation of HIV isolates during stavudine (D4T) therapy. Second National Confer- ence on Human Retroviruses and Related Infections. Wash-ington DC (29 January - 2 February 1995). Abstract 453.
   Google Scholar
• COAKLEY E, GILLES J, PENDEAULT L, DUNKLE L, HAMMER S: Susceptibilities of HIV-1 isolates derived from pa-tients treated with didanosine (ddl) and stavudine (d4T). Fourth Conference on Retroviruses and Opportunistic Infections. Fourth Conference on Retroviruses and Opportun-istic Infections. Washington DC (22–26 January 1997). Ab-stract 575.
   Google Scholar
• HARRIGAN PR, TISDALE M, NAJERA I et al.: Antiretroviral activity and resistance to 1592U89, a novel HIV RT inhibitor. Fifth International Workshop on HIV Drug Resis-tance. Whistler (3–6 July 1996). Abstract 16.
   Google Scholar
• KOHL NE, EMINI EA, SCHLEIF WA: Active human immu-nodeficiency virus protease is required for viral infec-tivity. Proc. Natl. Acad. ScL USA (1988) 85:4686–4690.
   PubMed Web of Science ®Google Scholar
• MOYLE G, GAZZARD B: Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs (1996) 51:701–712.
   PubMed Web of Science ®Google Scholar
• ROSE RE, GONG Y-F, GREYTOK JA et al: Human immu-nodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. Proc. Natl. Acad. ScL USA (1996) 93:1648–1653.
   PubMed Web of Science ®Google Scholar
• SMITH T, SWANSTROM R: Biological cross-resistance to HIV-1 protease inhibitor. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 15.
   Google Scholar
• FURFINE ES, MASCHERA B, BLAIR ED: Human immunode-ficiency virus resistance to saquinavir is mediated by protease: reduced affinity of mutant protease from saquinavir occurs from increased dissociation rate con-stants. Fifth International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 23.
   Google Scholar
• PAZHANISAMY S, PORTER M, STUVER CM et al: Kinetic characterization of resistant mutants of HIV protease. Fifth International Workshop on HIV Drug Resistance. Whis-tler (3–6 July 1996). Abstract 26.
   Google Scholar
• CONDRA JH, HOLDER DJ, GRAHAM DJ et al.: Genotypic or phenotypic susceptibility testing may not predict clinical response to indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 47.
   Google Scholar
• LECH WJ, WANG G, YANG YL et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistance variants in untreated subjects. J. Virol (1996) 70:2038–2043.
   PubMed Web of Science ®Google Scholar
• VASUDEVACHARI MB, ZHANG Y-M, IMAMICHI H et al.: Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detec-tion. Antimicrob. Agents Chemother. (1996) 40:2525–2541.
   Google Scholar
• YAMAGUCHI K, BYRN RA: Clinical isolates of HIV-1 contain few pre-existing proteinase inhibitor resis-tance-conferring mutations. Biochim. Biophys. Acta (1995) 1253:136–140.
   PubMed Web of Science ®Google Scholar
• WINSLOW DL, STACKS, KING R et al: Limited sequence diversity of the HIV type-1 protease gene from clinical isolates and in vitro susceptibility to HIV protease inhibitors. AIDS Res. Hum. Retrovir. (1995) 11:107–113.
   PubMed Web of Science ®Google Scholar
• EL-FARRASH MA, KURODA MJ, KITAZAKI T eta].: Genera-tion and characterization of a human immunodefi-ciency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J. Virol. (1994) 68:233–239.
   Google Scholar
• HO DD, TOYOSHIMA T, MO H et al.: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C-2 symmetric protease inhibi-tor. J. Vim]. (1994) 68:2016–2020.
   Web of Science ®Google Scholar
• KAGEYAMA S, ANDERSON BD, HOESTERY BL et al.: Pro-tein binding of human immunodeficiency virus pro-tease inhibitor KN1-272 and alteration of its in vitro antiretroviral activity in the presence of high concen-trations of proteins. Antimicrob. Agents Chemother. (1994) 38:1107–1111.
   PubMed Web of Science ®Google Scholar
• BILELLO JA, BILELLO PA, RICHARD M, ROBINS T, DRUSANO GL: Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency vi-rus protease, by human serum CKi acid glycoprotein. Infect. Dis. (1995) 171:546–551.
   Google Scholar
• FISCHL MA, RICHMAN DD, FLEXNER C et at Phase I study of two formulations and dose schedules of SC-52151, a protease inhibitor. Second National Conference on Human Retroviruses and Related Infections. Washington (1995). Ab-stract 186.
   Google Scholar
• MERRY C, BARRY MG, MULCAHY F et al.: Saquinavir pharmacokinetics alone and in combination with rito-navir in HIV-infected patients. AIDS (1997) 11:F29–F33.
   PubMed Web of Science ®Google Scholar
• VELLA S, GALLUZZO C, GIANNINI G etal.: Saquinavir/zi-dovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity. AntiTI-ral Res. (1996) 29:91–93.
   Google Scholar
• JACOBSEN H, YASARGIL K, WINSLOW DL et al.: Charac-terization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibi-tor Ro31-8959. Virology (1995) 206:527–534.
   PubMed Web of Science ®Google Scholar
• JACOBSEN H, HAENGGI M, OTT M eta].: Reduced sensi-tivity of saquinavir: An update on genotyping from Phasetrials. Fourth International Workshop on HIVDrug Resistance. Sardinia (1995). Abstract 68.
   Google Scholar
• JACOBSEN H HAENGGI M, OTT M et al.: In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies. J. Infect. Dis. (1996) 173:1379–1387.
   PubMed Web of Science ®Google Scholar
• VELLA S, LAZZARIN A, CAROSI G eta].: Saquinavir alone or in combination with zidovudine in previously un-treated patients with advanced HIV infection: a random-ized Phase I/11 controlled trial. Antiviral Ther. (1996) 1:129–140.
   Google Scholar
• SCHAPIRO JM, WINTERS MA, STEWART F et al.: The effect of high-dose saquinavir on viral load and CD4+ T-cell count in HIV-infected patients. Ann. Intern. Med. (1996) 124:1039–1050.
   PubMed Web of Science ®Google Scholar
• MASCHERA B, TISDALE M, DARBY G et al: In vitro growth characteristics of 11IV-1 variants with reduced sensitiv-ity to saquinavir explain the appearance of L9OM escape mutant in vivo. Fifth International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 85.
   Google Scholar
• EASTMAN PS, DUNCAN IB, GEE C, RACE E: Acquisition of genotypic mutations associated with reduced suscepti-bility to protease inhibitors during saquinavir mono- therapy. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 30.
   Google Scholar
• RACE E, SHELDON JG, KAYE S et al: Mutations associated with reduced sensitivity to saquinavir occur in a minor-ity of patients treated in combination with ddC: results from a Phase III clinical trial (NV14256). Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washing-ton DC (22–26 January 1997). Abstract 600.
   Google Scholar
• TOMLINSON PW, CRAIG JC, MOFFATT AR et al: 11IV-1 from patients in a Phase II clinical trial of the proteinase inhibitor (PO saquinavir (SQV) taken in combination with RT inhibitors (RTIs) exhibits very little reduced sensitivity to other PIs. AIDS (1996) 10\(Suppl. 2):S21 p12.
   Google Scholar
• SHELDON J, CRAIG C, RACE E et al.: Reduced sensitivity to saquinavir (SQV) occurs infrequently, associates only with 48V or 90M and is modest in degree. Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washing-ton DC (22–26 January 1997). Abstract 599.
   Google Scholar
• GAZZARD B, MOYLE G: To sequence or not to sequence? Exp. Opin. Invest. Drugs (1997) 6(2) :99–102.
   Google Scholar
• HIRSCHEL B, LORENZI P, YERLY S et al.: Escape of viremia and rapid development of protease mutations in ad-vanced HIV infection treated with saquinavir and rito-navir. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (22–26 January 1997). Abstract 594.
   Google Scholar
• CONDRA JH, HOLDER DJ, SCHLEIF WA et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibi-tor. J. Virol (1996) 70:8270–8276.
   PubMed Web of Science ®Google Scholar
• CONDRA JH, SCHLIEF WA, BLAHY OM eta].: Dynamics of acquired 11IV-1 clinical resistance to the protease inhibi-tor MK-639. Fourth International HIV Drug-Resistance Workshop. Sardinia (1995). Abstract 72.
   Google Scholar
• IV1ELLORS JW, MCMAHON DK, CHODAKEWITZ JA et al: Correlation between genotypic evidence of 11IV-1 resis-tance to the protease inhibitor MK-639 and loss of antiviral effect in treated patients. Fourth International Workshop on IffV Drug Resistance. Sardinia (1995). Abstract 71.
   Google Scholar
• EASTMAN PS, GEE C, DEWAR R eta].: An evaluation of Crixivan monotherapy and crbdvan/IL-2 combination therapy subjects. Fifth International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 34.
   Google Scholar
• EASTMAN PS, KELSO R, BOYER E et al.: Loss of suppres-sion of viral replication by ritonavir (ABT-538) is quan-titatively associated with the acquisition of genotypic mutations at codon 82 of the 11IV-1 protease gene. Third Conference on Retroviruses and Opportunistic Infections. Washington DC Oanuary-February 1996). Abstract 201.
   Google Scholar
• PAULOUS S, CLAVEL F: Sequential selection by protease inhibitors: effects of ritonavir resistance on further selection of HIV resistance to saquinavir. Fourth Confer-ence on Retroviruses and Opportunistic Infections. Washing-ton DC (22–26 January 1997). Abstract 598.
   Google Scholar
• MOLLA A, KEMPF D, KORNEYEVA M et al.: Charac-terization of the in vivo resistance pathway and phar-macokinetic properties of ritonavir. Fifth International Workshop on HIV Drug Resistance. Whistler (3–6 July 1996). Abstract 31.
   Google Scholar
• KEMPF D, MOLLA A, SUN E et al.: The duration of viral suppression is predicted by viral load during protease inhibitor therapy. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (22–26 January 1997). Abstract 603.
   Google Scholar
• PATICK AK, MO H, MARKOWITZ M et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. (1996) 40:292–297.
   PubMed Web of Science ®Google Scholar
• PATICK AK, DURAN M, CAO Y et al.: Genotypic analysis of 11IV-1 variants isolated from patients treated with the protease inhibitor Nelfinavir, alone or in combination with d4T or AZT and 3TC. Fourth Conference on Retroviruses and Opportunistic Infections. Washington DC (22–26 January 1997). Abstract 10.
   Google Scholar
• PARTELEDIS JA, YAMAGUCHI K, TISDALE M et at In vitro selection and characterization of human immunodefi-ciency virus type 1 (11IV-1) isolate with reduced sensi-tivity to hydroxy-ethylamino sulfonamide inhibitors of 11IV-1 aspartyl protease. J. Virol (1995) 69:5228–5235.
   PubMed Web of Science ®Google Scholar
• PAZHANISAMY S, STUVER CM, CULLINAN AB et al.: Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants. j Biol. Chem. (1996) 30:17979–17985.
   Google Scholar
• TISDALE M, MYERS RE, MASCHERA B et al.: Cross-resis-tance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. (1995) 39:1704–1710.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Influence of emergence of viral resistance on HIV treatment choice. Int. J. STD and AIDS (1995) 6:225–226.
   PubMed Web of Science ®Google Scholar
• MOYLE GJ: Use of viral resistance patterns to antiretrovi-ral drugs in optimising selection of drug combinations and sequences. Drugs (1996) 52:168–185.
   PubMed Web of Science ®Google Scholar
• KOHLSTAEDT LA, WANG J, FRIEDMAN JM, RICE PA, STEITZ TA: Crystal structure at 3.5 A resolution of 11IV-1 reverse transcriptase complexed with an inhibitor. Science (1992) 256:1783–1790.
   Google Scholar
• D'AQUILLA RT: 11IV-1 drug resistance: molecular patho-genesis and laboratory monitoring. Clinics in Lab. Med. (1994) 14:393-423. Review of laboratory aspects of resistance.
   Google Scholar
• ARNOLD E, DING J, HUGHES SH, HOSTOMSKY Z: Struc-tures of DNA and RNA polymerases and their interac-tions with nucleic acid substrates. CUIT. Opin. Struct. Biol. (1995) 5:27–38.
   PubMed Web of Science ®Google Scholar
• RICHMAN DD, HAVLIR D, CORBEIL J: Nevirapine resis-tance mutations of human immunodeficiency virus type 1 selected during therapy. J. Vim]. (1994) 68:1660–1666.
   Web of Science ®Google Scholar
• RICHMAN DD, SHIH C-K, LOWY I eta].: Human immu-nodeficiency virus type 1 mutants resistant to nonnu-cleoside inhibitors of reverse transcriptase arise in tissue culture. Proc. Natl. Acad. Sci. USA (1991) 88:11241–11245.
   Google Scholar
• HAVLIR DV, EASTMAN S, GAMST A, RICHMAN DD: Nevi-rapine -resistant human immunodeficiency virus: ki-netics of replication and estimated prevalence in untreated patients. J. Virol (1996) 70:7894–7899.
   PubMed Web of Science ®Google Scholar
• DEJONG MD, LOEWENTHL M, BOUCHER CAB eta].:Alter- nating nevirapine and zidovudine treatment of human © Ashley Publications Ltd. All rights reserved.Exp. Opin. Invest. Drugs (1997) 6(8) immunodeficiency virus type 1 infected persons does not prolong nevirapine activity. J. Infect. Dis. (1994) 169:1346–1350.
   Google Scholar
• D'AQUILA RT, HUGHES MD, JOHNSON VA et al: Nevirap-ine, zidovudine, and didanosine compared with zi-dovudine and didanosine in patients with HIV-1 infection; a randomized, double-blind placebo-control-led trial. Ann. Intern. Med. (1996) 124:1019–1030.
   PubMed Web of Science ®Google Scholar
• MURPHY RL, MONTANER J: Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp. Opin. Invest. Drugs (1996) 5 (9) :1183–1199.
   Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ M-J eta].: Human immunodeficiency virus type 1-specific [2',5'-bis-0-(tert-butyldimethylsily0-b-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole-2",2"-dioxide) purine ana-logs show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-spe-cific non-nucleoside analogues. Mol. PharmacoL (1993) 43:109–114.
   Google Scholar
• KARLSSON A, BALZARINI, J PEREZ-PEREZ MJ, CAMARASA MJ, DECLERCQ E: Human immunodeficiency virus type 1 (HIV-1) strains emerging after drug therapy. Second International HIV Drug Resistance Workshop. Noordwijk (1993).
   Google Scholar
• BALZARINI J, KARLSSON A, PEREZ-PEREZ M-J et al: HIV-1 specific reverse transcriptase inhibitors show differen-tial activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse tran-scriptase. Virology (1992) 192:246–253.
   Web of Science ®Google Scholar
• DUEWEKE TJ, PUSHKARSKAYA T, POPPE SM et al: A mutation in reverse transcriptase of Ms [heteroaryl] piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other non-nucleoside inhibitors. Proc. Nail Acad. Sci. USA (1993) 90:4713–4717.
   PubMed Web of Science ®Google Scholar
• DEMETER LM, SHAFER RW, PARA M et al.: Delavirdine susceptibility of HIV-1 isolates obtained from patients receiving DLV monotherapy. J. AIDS Hum. Retrovir. (1995) 10:S11.
   Google Scholar
• BEN-TIKTAK AMM, JOLY V, SITBON G etal.: Combination therapy with delavirdine mesylate (DLV) and AZT: vi-rology data from a European Phase II trial.' AIDS Hum. Retrovir. (1995) 10:S23–S24.
   Google Scholar
• DEMETER LM, MEEHAN PM, MORSE G et al: HIV-1 suscep-tibilities and reverse transcriptase mutations in pa-tients receiving combination therapy with didanosine and delavirdine. J. AIDS Hum. Retrovir. (1997) 14:136–144.
   PubMedGoogle Scholar
• STAZEWSKI S, MILLER V, KOBER A et al: Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1 infected patients. Antiviral 7her. (1996) 1:42–50.
   PubMedGoogle Scholar
• STAZEWSKI S, MILLER V, REHMET S et al.: Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1 infected patients. AIDS (1996) 10:F1–F7.
   PubMed Web of Science ®Google Scholar
• WINSLOW DL, GARBER S, REID C et al.: Selection condi-tions affect the evolution of specific mutations in re-verse transcriptase gene associated with resistance to DMP 266. AIDS (1996) 10:1205–1209.
   PubMed Web of Science ®Google Scholar
• KLEIM J-P, ROSNER M, WINKLER I et al: Nucleoside RT inhibitor specific mutations within the HIV-1 pol gene selected with a non-nucleoside type RT inhibitor. Fourth International Workshop on HIV Drug Resistance. Sardinia (1995). Abstract 3.
   Google Scholar
• ST CLAIR MH, HARTIGAN PM, ANDREWS JC et al.: Zi-dovudine resistance, syncytiurn-inducing phenotype and HIV disease progression in a case control study. J. AIDS (1993) 6:891–897.
   PubMed Web of Science ®Google Scholar
• WILDEMANN B, HAAS J, EHRHART K et al: In vivo com-parison of zidovudine resistance mutations in blood and CSF of HIV-1 infected patients both simultaneously in plasma but also between different body compart-ments such as blood and CSF. Neurology (1993) 43:2659–2663.
   PubMed Web of Science ®Google Scholar
• DELASSUS S, CHEYNIER R, WAIN-HOBSON S: Nonhomo-geneous distribution of human immunodeficiency vi-rus type 1 proviruses within the spleen. J. Virol (1992) 66:5642–5645.
   PubMed Web of Science ®Google Scholar
• KORBER BTM, KUNSTMAN KJ, PATTERSON BK et al.: Genetic differences between blood- and brain-derived viral sequences from human immunodeficiency virus type 1-infected patients: evidence of conserved ele-ments in the V3 region of the envelope protein of brain-derived sequences. J. Virol (1994) 68:7467–7481.
   PubMed Web of Science ®Google Scholar
• BALL JK, HOLMES EC, WHITWELL H, DESSELBERGER U: Genomic variation of human immunodeficiency virus type 1 (HIV-1): molecular analyses of HIV-1 in sequen-tial blood samples and various organs obtained at autopsy. J. Gen. Virol (1994) 75:867–879.
   Web of Science ®Google Scholar
• PORTEGIES P: HIV-1, the brain, and combination ther-apy. Lancet (1995) 346:1244–1245.
   PubMed Web of Science ®Google Scholar
• DI STEFANO M, NORKANS G, CHIODI F eta].: Zidovudine-resistant variants of HIV-1 in brain. Lancet (1993) 342:865.
   Google Scholar
• LUIZZI G, CHIRIANNI A, CLEMENTI M et al.: Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS (1996) 10:F51–F56.
   PubMed Web of Science ®Google Scholar
• GAZZARD BG, MOYLE GJ: Individualisation of HIV ther-apy: the clinician's perspective. Br. J. Clin. Pract. (1995) 49:145–147.
   PubMedGoogle Scholar
• KOZAL MJ, SHAFER RW, WINTERS MA, KATZENSTEIN DA, MERIGAN TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lympho-cyte numbers in long-term zidovudine recipients. J. Infect. Dis. (1993) 167:526–532.
   PubMed Web of Science ®Google Scholar
• OGINO MT, DANKER VVM, SPECTOR SA: Development and significance of zidovudine resistance in children infected with human immunodeficiency virus. J. Pediatr. (1993) 123:1–8.
   PubMed Web of Science ®Google Scholar
• SAAG MS, EMINI EA, LASKIN OL et al: A short term clinical evaluation of L-697,661, a non-nucleoside inhibitor of HIV-1 reverse transcriptase: L-697,661 working group. New Engl. J. Med. (1993) 329:1065–1072.
   PubMed Web of Science ®Google Scholar
• KATZENSTEIN DA, HAMMER SM, HUGHES MD et al: The relation of virologic and immunologic markers to clini-cal outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 cells per cubic millimeter. New Engl. Med. (1996) 335:1091–1098.
   PubMed Web of Science ®Google Scholar
• O'BRIEN WA, HARTIGAN P, MARTIN D et al: Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. New Engl. J. Med. (1996) 334:426–443.
   PubMed Web of Science ®Google Scholar
• PHILLIPS AN, ERON JJ, BARTLETT JA et al.: 11IV-1 RNA levels and the development of clinical disease. AIDS (1996) 10:859–865.
   PubMed Web of Science ®Google Scholar
• SAAG MS, HOLODNIY M, KURITZKES DR etal.: HIV viral load markers in clinical practice. Nature Med. (1996) 2:625-629. Guidelines for using viral load test.
   Google Scholar
• TUDOR-WILLIAMS G, ST CLAIR MH, MCKINNEY RE et al.: HIV-1 sensitivity to zidovudine and clinical outcome in children. Lancet (1992) 339:15–19.
   PubMed Web of Science ®Google Scholar
• MONTANER JSG, SINGER J, SCHECHTER MR eta].: Clinical correlates of in vitro HIV-1 resistance to zidovudine. Results of the multicenter Canadian AZT trial. AIDS (1993) 7:189–196.
   Google Scholar
• PRINCIPI N, MARCHISIO P, PASQUALE M et al.: HIV-1 reverse transcriptase codon 215 mutation and clinical outcome in children treated with zidovudine. AIDS Res. Hum. Retrovir. (1994) 19:721–726.
   Google Scholar
• D'AQUILA RT, JOHNSON VA, WELLES SL etal.: Zidovudine resistance and 11IV-1 disease progression during an-tiretroviral therapy. Ann. Intern. Med. (1995) 122:401–408.
   Google Scholar
• TREMBLAY M, ROOKE R, WAINBERG MA: Zidovudine-re-sistant and -sensitive 11IV-1 isolates from patients on drug therapy: in vitro studies evaluating level of repli-cation-competent viruses and cytopathogenicity. AIDS (1992) 6:1445–1449.
   PubMed Web of Science ®Google Scholar
• MILLER V, HERTOGS K, DE BETHUNE M-P etal.: Incidence of 11IV-1 resistance and cross-resistance to protease inhibitors after indinavir failure: impact on subsequent ritonavir/saquinavir therapy. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 81. First report of using other PIs after indinavir.
   Google Scholar
• BODSWORTH N, HEAPS M, GOSLING D, MCNALLY L:
   Google Scholar
• •Efficacy of indinavir (IDV) and Ritonavir (RTV) in patients pretreated with saquinavir (SQV). Seventh Inter-national Antiviral Symposium. Sydney (17–19 February 1997). Abstract. Activity of RTV and IDV after SQV.
   Google Scholar
• SCHAPIRO JM, WINTERS M, LAWRENCE J, NORRIS J, MERI-
   Google Scholar
• •GAN TC: Clinical and genotypic cross-resistance be-tween protease inhibitors saquinavir and indinavir. International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg, Florida (25–28 June 1997). Abstract 87. Activity of IDV after SQV.
   Google Scholar
• MELLORS JW, LARDER BA, SCHINAZI RF: Mutations in retroviral genes associated with drug resistance. Int. Antiviral News (1996) 4:95-107. Listings of the mutations.
   Google Scholar